---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-031741"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:17:26.707747+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix to present positive UroShield study at ICS 2023; reduces CAUTI and blockages

## Summary
- Dr. Sandra Wilks to present UroShield study at ICS 2023 in Toronto on September 27.
- University of Southampton study shows UroShield reduces catheter-associated urinary tract infections and blockages.
- Study suggests UroShield may promote healthy urinary microbiome and reduce antibiotic use.
- UroShield uses low-frequency ultrasound to prevent bacterial biofilm on catheters.

## SEC filing metadata
- accession: 0001493152-23-031741
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315223031741/0001493152-23-031741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315223031741/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-031741
- JSON: https://secwatch.observer/filing/0001493152-23-031741.json
- Plain text: https://secwatch.observer/filing/0001493152-23-031741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.